請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19090
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊家榮 | |
dc.contributor.author | Yi-Jyun Lin | en |
dc.contributor.author | 林怡君 | zh_TW |
dc.date.accessioned | 2021-06-08T01:44:44Z | - |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-15 | |
dc.identifier.citation | 1 Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2 Falkenberg KJ, Johnstone RW: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13:673-691. 3 Gryder BE, Sodji QH, Oyelere AK: Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4:505-524. 4 Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, Turner BM: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751-1759. 5 Kramer OH, Mahboobi S, Sellmer A: Drugging the HDAC6-Hsp90 interplay in malignant cells. Trends Pharmacol Sci 2014;35:501-509. 6 Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, Matthias P: Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008;28:1688-1701. 7 Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, Harrison TR, McGraw-Hill Companies., AccessMedicine (Online service): Harrison's principles of internal medicine. New York, N.Y., McGraw-Hill Medical, 2015, pp 1 online resource. 8 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. 9 Yamamoto JF, Goodman MT: Patterns of leukemia incidence in the united states by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008;19:379-390. 10 Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM: Acute leukemia incidence and patient survival among children and adults in the united states, 2001-2007. Blood 2012;119:34-43. 11 Ward E, DeSantis C, Robbins A, Kohler B, Jemal A: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64:83-103. 12 Chiaretti S, Zini G, Bassan R: Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014;6:e2014073. 13 Estey EH: Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89-99. 14 Burger B, Zimmermann M, Mann G, Kuhl J, Loning L, Riehm H, Reiter A, Schrappe M: Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21:184-188. 15 Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951. 16 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-458. 17 Estey EH, Appelbaum FR, SpringerLink (Online service): Leukemia and related disorders integrated treatment approaches. New York, NY, Springer Science+Business Media, LLC, 2012, pp xiii, 380 p. 18 Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924-1930. 19 Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH: Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international all trial: Mrc ukall xii/ecog e2993. Blood 2005;106:3760-3767. 20 Harris MB, Shuster JJ, Pullen DJ, Borowitz MJ, Carroll AJ, Behm FG, Land VJ: Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: A pediatric oncology group study. J Clin Oncol 1998;16:2840-2847. 21 Ho E, Clarke JD, Dashwood RH: Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 2009;139:2393-2396. 22 d'Ydewalle C, Bogaert E, Van Den Bosch L: HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic 2012;13:771-779. 23 Nalabothula N, Carrier F: Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 2011;3:145-155. 24 Wolbrette DL: Drugs that cause torsades de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep 2004;6:379-384. 25 Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN: Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-1802. 26 Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-607. 27 Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks PA: HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A 2008;105:9633-9638. 28 Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, Seto E: HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007;27:197-213. 29 Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-458. 30 Subramanian C, Jarzembowski JA, Opipari AW, Jr., Castle VP, Kwok RP: HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 2011;13:726-734. 31 Seidel C, Schnekenburger M, Dicato M, Diederich M: Histone deacetylase 6 in health and disease. Epigenomics 2015;7:103-118. 32 Li Y, Shin D, Kwon SH: Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J 2013;280:775-793. 33 Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB: Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008;14:7340-7347. 34 Kanno K, Kanno S, Nitta H, Uesugi N, Sugai T, Masuda T, Wakabayashi G, Maesawa C: Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol Rep 2012;28:867-873. 35 Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, Kim N, Ham WS, Breslow R, Marks PA: Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci U S A 2013;110:15704-15709. 36 Savill J, Fadok V: Corpse clearance defines the meaning of cell death. Nature 2000;407:784-788. 37 Vucic D, Dixit VM, Wertz IE: Ubiquitylation in apoptosis: A post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011;12:439-452. 38 Lapenna S, Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-566. 39 Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7:335-346. 40 Lindahl T, Barnes DE: Repair of endogenous DNA damage. Cold Spring Harb Symp Quant Biol 2000;65:127-133. 41 Hoeijmakers JH: DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-1485. 42 Ciccia A, Elledge SJ: The DNA damage response: Making it safe to play with knives. Mol Cell 2010;40:179-204. 43 Chowdhury D, Choi YE, Brault ME: Charity begins at home: Non-coding RNA functions in DNA repair. Nat Rev Mol Cell Biol 2013;14:181-189. 44 Hada M, Kwok RP: Regulation of Ku70-Bax complex in cells. J Cell Death 2014;7:11-13. 45 Song Y, Brady ST: Post-translational modifications of tubulin: Pathways to functional diversity of microtubules. Trends Cell Biol 2015;25:125-136. 46 Kline-Smith SL, Walczak CE: Mitotic spindle assembly and chromosome segregation: Refocusing on microtubule dynamics. Mol Cell 2004;15:317-327. 47 Li L, Yang XJ: Tubulin acetylation: Responsible enzymes, biological functions and human diseases. Cell Mol Life Sci 2015;72:4237-4255. 48 Howes SC, Alushin GM, Shida T, Nachury MV, Nogales E: Effects of tubulin acetylation and tubulin acetyltransferase binding on microtubule structure. Mol Biol Cell 2014;25:257-266. 49 Bray F, Jemal A, Grey N, Ferlay J, Forman D: Global cancer transitions according to the human development index (2008-2030): A population-based study. Lancet Oncol 2012;13:790-801. 50 Al-Lazikani B, Banerji U, Workman P: Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-692. 51 Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55. 52 Chou TC: Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 2010;70:440-446. 53 Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101. 54 Batchu SN, Brijmohan AS, Advani A: The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci (Lond) 2016;130:987-1003. 55 Chaudhary N, Nakka KK, Chavali PL, Bhat J, Chatterjee S, Chattopadhyay S: Smar1 coordinates HDAC6-induced deacetylation of Ku70 and dictates cell fate upon irradiation. Cell Death Dis 2014;5:e1447. 56 Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA: Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma. Clin Cancer Res 2015;21:4663-4675. 57 Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N: Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-2589. 58 Hackanson B, Rimmele L, Benkisser M, Abdelkarim M, Fliegauf M, Jung M, Lubbert M: HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res 2012;36:1055-1062. 59 Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, Reinhardt D, Li Z, Orkin SH, Behrens GM, Klusmann JH: Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014;28:577-588. 60 Dalton WT, Jr., Ahearn MJ, McCredie KB, Freireich EJ, Stass SA, Trujillo JM: HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 1988;71:242-247. 61 Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G: Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174-1182. 62 Namdar M, Perez G, Ngo L, Marks PA: Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A 2010;107:20003-20008. 63 Lee JH, Yao Y, Mahendran A, Ngo L, Venta-Perez G, Choy ML, Breslow R, Marks PA: Creation of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci U S A 2015;112:12005-12010. 64 Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58. 65 Volkova M, Russell R, 3rd: Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7:214-220. 66 Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE: Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015;313:815-823. 67 Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-1642. 68 Venkatesan B, Prabhu SD, Venkatachalam K, Mummidi S, Valente AJ, Clark RA, Delafontaine P, Chandrasekar B: Wnt1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal 2010;22:809-820. 69 Wolf D, Rotter V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A 1985;82:790-794. 70 Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spears CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV: Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 1998;4:1315-1322. 71 Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B: Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst) 2003;2:49-60. 72 Brown KD, Lataxes TA, Shangary S, Mannino JL, Giardina JF, Chen J, Baskaran R: Ionizing radiation exposure results in up-regulation of Ku70 via a p53/ataxia-telangiectasia-mutated protein-dependent mechanism. J Biol Chem 2000;275:6651-6656. 73 Robert C, Nagaria PK, Pawar N, Adewuyi A, Gojo I, Meyers DJ, Cole PA, Rassool FV: Histone deacetylase inhibitors decrease nhej both by acetylation of repair factors and trapping of parp1 at DNA double-strand breaks in chromatin. Leuk Res 2016;45:14-23. 74 Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265. 75 Mollinedo F, Gajate C: Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-450. 76 Gascoigne KE, Taylor SS: How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579-2585. 77 Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM: The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol 2015;8:82. 78 Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, Kabarriti R, Xenias HS, Mazitschek R, Hubbert C, Kawaguchi Y, Sheetz MP, Yao TP, Bulinski JC: HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007;120:1469-1479. 79 Zilberman Y, Ballestrem C, Carramusa L, Mazitschek R, Khochbin S, Bershadsky A: Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci 2009;122:3531-3541. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19090 | - |
dc.description.abstract | 實驗目的:急性白血病的標準化療於目前臨床上有其限制,vincristine 與doxorubicin皆為急性白血病的常用藥物,然而兩者分別具有神經毒性與心毒性等嚴重副作用,且抗藥性的問題亦逐漸出現,故需要提供其他有效的治療策略。組蛋白去乙醯酶6(histone deacetylase 6,HDAC6)被發現在急性白血病細胞中異常增加且參與癌細胞的調控,故抑制HDAC6 被認為是有潛力的急性白血病細胞治療策略。藥物合併治療的目的在於降低個別藥物的使用劑量,增強療效、減低藥物產生不良反應的機會,是癌症治療常見的用藥方式。本研究目的為探討新型HDAC6 抑制劑Compound A 分別與vincristine 或doxorubicin 進行藥物合併治療對於急性白病細胞的抑制情形與機轉。
實驗方法:本文透過細胞存活檢測試驗評估不同藥物濃度下細胞的存活情形,並利用流式細胞儀觀察細胞週期的分佈。細胞內蛋白質的表現由西方墨點法偵測。免疫沉澱法用以檢測Ku70 乙醯化、Ku70 與Bax 間的作用,以及Ku70 與γ-H2AX間的作用;藉由HDAC6 過量表現的方式確認Compound A 的作用機轉是否來自於其抑制HDAC6 活性。藥物合併指數由CompuSyn 軟體計算出。 實驗結果:Compound A 與doxorubicin 合併使用能促進急性骨髓性白血病細胞株HL-60 之DNA 損害反應,調控Ku70 乙醯化與Bax 轉移至粒線體,進而造成協同性細胞凋亡;而Compound A 與vincristine 合併使用會干擾微小管的動態平衡,使急性淋巴性白血病細胞株MOLT-4 停滯在有絲分裂週期,細胞無法正常分裂而死亡。證實HDAC6 抑制劑與doxorubicin 或vincristine 合併使用能增加藥物療效,是有潛力的治療方式。 結論:本研究提供HDAC6 抑制劑的研發方向與急性白血病治療的發展策略,經由合併藥物的治療方式增強療效,降低個別藥物劑量。 | zh_TW |
dc.description.abstract | Objective. There are some limitations of standard chemotherapy for acute leukemia. Vincristine and doxorubicin are commonly used for acute leukemia, but they may induce cardiomyopathy and neurotoxicity, respectively. Furthermore, chemotherapy resistance occurs more and more frequently. Therefore, the effective treatment strategies are needed. Histone deacetylase 6 inhibition is considered as a potential therapeutic strategy for acute leukemia, since it is observed that HDAC6 is overexpress in acute leukemia and regulates tumor survival. Combination therapy for cancer is used to minimize adverse drug effects, reduce drug dosage, enhance efficacy, and prevent drug resistance. In order to enhance efficacy of chemotherapy drugs of acute leukemia, this study will investigate the effects of combination Compound A, a histone deacetylase 6 inhibitor, with doxorubicin or vincristine on human acute leukemia cells.
Methods. Cell viability experiments were determined by MTT assay, and cell cycle distributions was analyzed by flow cytometry. Protein expression was evaluated by Western blot. Immuneprecipitation was used to detect acetylation of Ku70, interaction between Bax and Ku70, and Ku70 interaction with γ-H2AX. Overexpression HDAC6 to ensure the anti-cancer effect of Compound A through inhibition HDAC6 activity. The combination index was measured by CompuSyn software. Results. Combination Compound A and doxorubicin induces DNA damage respond on human acute myeloid leukemia cell line HL-60. Compound A can also increase Ku70 acetylation and release Bax to mitochondria. Thus, combination Compound A and doxorubicin induce cell death synergistically. Combination Compound A and vincristine, by constant, may alter microtubule dynamics, triggering acute lymphoblastic leukemia cell line MOLT-4 arrest in mitosis followed by induction of the apoptotic pathway. Conclusion. The results demonstrate the novel strategy for the treatment of acute leukemia by combination HDAC6 inhibitor with chemotherapy drugs. The combination therapy can induce efficacy effects with lower doses of individual drugs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:44:44Z (GMT). No. of bitstreams: 1 ntu-105-R03423017-1.pdf: 34507800 bytes, checksum: f2bcd29443ddc9654fb0b473951c32f2 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 誌謝………………………………………………………………………I
縮寫表……………………………………………………………………II 中文摘要…………………………………………………………………III 英文摘要…………………………………………………………………IV 第一章 研究動機與目的………………………………………………1 第二章 文獻回顧………………………………………………………2 第三章 實驗材料與方法………………………………………………24 第四章 實驗結果………………………………………………………31 第五章 討論……………………………………………………………38 第六章 結論與未來展望………………………………………………44 參考文獻………………………………………………………………63 | |
dc.language.iso | zh-TW | |
dc.title | 新型HDAC6 抑制劑合併化療藥物於人類急性白血病之抗癌作用探討 | zh_TW |
dc.title | The anti-cancer effects of novel HDAC6 inhibitor combination with chemotherapeutic agents in human acute leukemia | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 劉景平,潘秀玲 | |
dc.subject.keyword | 組蛋白去乙醯?6,急性白血病,合併藥物治療,Ku70,微小管動態, | zh_TW |
dc.subject.keyword | Histone deacetylase 6,acute leukemia,combination therapy,Ku70,microtubule dynamics, | en |
dc.relation.page | 70 | |
dc.identifier.doi | 10.6342/NTU201602773 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 33.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。